Proactive Investors - Run By Investors For Investors

Midatech Pharma trading in line with forecasts with focus turning to clinical trials

The three studies will be closely monitored by investors
results graphic
The trading update showed revenues were going in the the right direction, while Midatech said its US arm broke even in the second-half

Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP) said trading last year was in line with forecasts with the focus in 2018 turning to three key clinical trials.

A first in-human study of Q-Octreotide, for the treatment carcinoid cancer and the hormonal disorder acromegaly, is expected to complete late this year or early next year.

READ: Critical year ahead of drug development for Midatech Pharma

A clinical assessment of MTX110, an investigational nano-inclusion product for the treatment of the fatal childhood brain cancer, Diffuse Intrinsic Pontine Glioma (DIPG), is expected to read out towards the end of 2019. 

Phase IV trial

Midetech is also carrying out a phase IV trial of cancer care product Gelclair that could expand its addressable market. This will assess its use in stem cell patients suffering oral mucositis, a side-effect of the treatment.

Unlike many other drug development companies the nano-technology specialist has a revenue-generating commercial operation which sells four cancer care support products.

In an update on its trading, the firm said turnover for 2017 would likely be in the order of £7.4mln, up from £6.9mln and in line with market forecasts. US product sales are expected to be up by 29% at £6.7mln. Midatech said the American unit reached  break-even in the second-half.

Net cash balance December 2017 31 was £13.2m – also in line with forecasts.

View full MTPH profile View Profile

Midatech Pharma Plc Timeline

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
January 03 2018
Investors have been cheered by the method used to raise fresh investment, which avoids the need to issue more shares for cash

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use